Heart disease is often associated with the heart and arteries, but its effects extend far beyond the cardiovascular system.

D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular ...

Discover how your diet can improve vision health with essential nutrients, carotenoids, and food pairings for long-term eye ...

For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

Macular degeneration is a prevalent eye disorder that typically results in loss of vision in individuals who are 50 years of age and older. Although there isn’t a recognized cure for this ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

BMO Capital analyst Kostas Biliouris downgraded the rating on 4D Molecular Therapeutics (FDMT – Research Report) to a Hold today, setting a ...

Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...